Alert: Beta Bionics shares slid from a Class Period high of $31.99 to under $9 across three disclosure events, as a securities class action contends the Company minimized an FDA Form 483 citing more than 18,000 unreported iLet complaints.

NEW YORK, Oct. 7, 2026 /PRNewswire/ — Levi & Korsinsky, LLP alerts investors in Beta Bionics, Inc. (NASDAQ: BBNX) that a securities class action was filed on behalf of shareholders who purchased securities between July 30, 2025 and February 24, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

BBNX traded at $31.99 per share on January 8, 2026. By April 10, 2026, the stock closed under $9, roughly $23.09 per share below that level, a decline of approximately 72% that erased hundreds of millions of dollars in market capitalization. Investors have until November 3, 2026 to seek appointment as lead plaintiff.

Three Disclosures, Three Market Declines

The decline did not arrive in one move. After the January 8, 2026 after-market report of an unexpectedly low number of new iLet patient starts, shares fell $11.85 to close at $20.14 the following session, a 37% single-day drop. On January 30, 2026, a Form 8-K disclosing receipt of an FDA Warning Letter citing non-conformities in Quality Management System, Medical Device Reporting, and Correction and Removals took shares from $14.79 to $13.83.

Market Impact by the Numbers

• Class Period high: $31.99 per share on January 8, 2026
• January 9, 2026: $11.85 per share decline (approximately 37%) to a $20.14 close
• January 30, 2026: $0.96 per share decline (approximately 6.5%) to a $13.83 close
• February 24-25, 2026: shares fell from a February 24 open of $13.55 to a February 25 close of $12.89 after the FDA publicly released the full 10-page Warning Letter
• April 10, 2026: shares closed under $9, roughly 72% below the Class Period high
• Aggregate market capitalization loss: hundreds of millions of dollars

What the Market Was Allegedly Not Pricing

The pleading asserts that a June 2025 FDA Form 483 identified more than 18,000 uninvestigated iLet complaints against a base of 29,419 users, including events described as life threatening. The complaint charges that management characterized those regulatory concerns as a “very benign” difference in interpretation of reporting rules, and that share prices reflected that characterization until the FDA’s own language reached the public in February 2026.

“When the price of a security reflects assurances that later prove incomplete, the correction can be severe, and here the complaint alleges shareholders absorbed roughly $23.09 per share between January and April 2026. Investors are entitled to a full accounting of what was known about the iLet Form 483 and when.” — Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years. Investors who suffered losses have until November 3, 2026 to seek appointment as lead plaintiff.

Frequently Asked Questions About the BBNX Lawsuit

Q: Who are the defendants named in the BBNX lawsuit? A: The complaint names Beta Bionics, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: How much did BBNX stock drop? A: Shares fell approximately 72%, a decline of about $23.09 per share from the Class Period high, after the Company disclosed an unexpected miss on new iLet patient starts and receipt of an FDA Warning Letter that the FDA later released publicly. Investors who purchased shares during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.

Q: What is the BBNX class action lawsuit about? A: A securities class action has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging materially false and misleading statements between July 30, 2025 and February 24, 2026. Shares fell approximately 72% after the Company disclosed weak iLet patient starts and an FDA Warning Letter citing Quality Management System, Medical Device Reporting, and Correction and Removals non-conformities. Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation.

Q: What do BBNX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my BBNX shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bbnx-upcoming-deadline-levi–korsinsky-alerts-beta-bionics-inc-stockholders-of-securities-class-action—contact-the-firm-302900698.html

SOURCE Levi & Korsinsky, LLP